Anapharm Bioanalytics Secures Funding from Eurostars and CDTI for Innovative Project on Therapy and Diagnosis of Ewing Sarcoma

Barcelona, April 18th, 2023 - Anapharm Bioanalytics, a leading bioanalytical contract research organization (CRO), is delighted to announce the successful acquisition of funding from the Eurostars-3 joint program, with co-funding from CDTI (Centre for Industrial Technological Development) and the European Union's Horizon Europe Research and Innovation Framework. This funding marks a significant milestone for the groundbreaking project, a collaborative effort between Anapharm Bioanalytics, iCellate Medical, and Aptadel Therapeutics.

The project endeavours to develop an innovative therapy and complementary diagnostic for Ewing Sarcoma, a rare childhood cancer. The project's flagship product, ADEL-101, entails an RNA-based aptamer specifically designed to target Ewing Sarcoma cells, combined with an RNA drug that effectively eliminates these cancer cells. The project will encompass comprehensive analyses of the drug's efficacy, mode of action, safety, toxicology, and pharmacokinetics, alongside the development of a companion diagnostic.

Each consortium member plays a pivotal role in the project, contributing their expertise and capabilities. Anapharm Bioanalytics, a specialized bioanalytical CRO, will spearhead the development of a bioanalytical test aimed at tracking the drug candidate ADEL-101 within the body. iCellate Medical, a leading Swedish medtech company, will be instrumental in the creation of a companion diagnostic kit to ensure the safe and effective utilization of ADEL-101 in human patients. Additionally, Aptadel Therapeutics, a Spanish biotech company, brings their cutting-edge RNA aptamer-based technology to the consortium, facilitating the development of a new class of drug conjugates.

This project has received funding from the Eurostars-3 joint program with co-funding from CDTI and the Horizon Europe Research and Innovation Framework of the European Union. Subsidized by CDTI. The company extends its deepest gratitude to these institutions for their commitment to advancing innovative research in the field of Ewing Sarcoma. It is important to note that any communication or publication regarding the project reflects solely the opinions of the authors, and neither CDTI nor the European Commission bears responsibility for the use that may be made of the information contained therein.


18/03/2024 12:36

Anapharm Bioanalytics Brazilian ANVISA Certificate Renewal

Anapharm Bioanalytics is proud to announce that it has recently renewed its ANVISA (Brazil) certification which is now valid until February 26th, 2026.

03/06/2022 12:39

Challenges in the Development of a Method for the Detection of Anti-PEGylated-aptamer Antibodies

Immunogenicity assays capable of properly determining the presence of anti-drug antibodies (ADA) and anti-PEG antibodies have been recognized of great importance due to the fact that pre-existing anti-PEG antibodies could have an impact on the efficacy of a drug coupled to polyethylene glycol (PEG).

26/05/2022 11:39

Challenges in the determination of two analytes with different physicochemical properties, Tapinarof and its main metabolite, Tapinarof Sulfate, at the low picogram level

The challenge of developing a new bioanalytical method considerably increases when two or more metabolites need to be simultaneously analysed. Their extraction and chromatography optimization can be further complicated if their physicochemical properties vary significantly. Method development may be even more difficult when low limits of quantitation are required, for instance, when evaluating the systemic adsorption of topical drugs.